Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
SONN 
Sonnet Biotherapeutics Holdings Inc (SONN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: SONN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -57.03% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.89M USD | Price to earnings Ratio - | 1Y Target Price 20 |
Price to earnings Ratio - | 1Y Target Price 20 | ||
Volume (30-day avg) 57257 | Beta 1.01 | 52 Weeks Range 1.22 - 16.80 | Updated Date 04/1/2025 |
52 Weeks Range 1.22 - 16.80 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -10.45 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -284.94% |
Management Effectiveness
Return on Assets (TTM) -133.99% | Return on Equity (TTM) -285.35% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -642507 | Price to Sales(TTM) 3.89 |
Enterprise Value -642507 | Price to Sales(TTM) 3.89 | ||
Enterprise Value to Revenue 35.91 | Enterprise Value to EBITDA -0.21 | Shares Outstanding 3065700 | Shares Floating 3007943 |
Shares Outstanding 3065700 | Shares Floating 3007943 | ||
Percent Insiders 1.58 | Percent Institutions 3.06 |
Analyst Ratings
Rating 5 | Target Price 160 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Sonnet Biotherapeutics Holdings Inc
Company Overview
History and Background
Sonnet Biotherapeutics Holdings, Inc. is a clinical-stage oncology company focused on developing innovative immunotherapeutic medicines. Founded to exploit targeted cytokine therapeutics, they aim to improve the safety and efficacy of cancer treatment. The company has progressed through various research and development stages, focusing on its Fully Human Albumin Binding (FHAB) platform to deliver cytokines to the tumor microenvironment.
Core Business Areas
- Oncology Therapeutics Development: Focuses on developing and commercializing innovative immunotherapies for cancer patients using its FHAB technology.
- FHAB Platform Technology: Developing and utilizing their proprietary FHAB platform to enhance the delivery of cytokines to tumor sites, improving treatment outcomes.
Leadership and Structure
The company's leadership team consists of experienced professionals in the fields of oncology, drug development, and biotechnology. The organizational structure likely includes departments for research and development, clinical trials, regulatory affairs, and corporate management. Pankaj Mohan serves as CEO.
Top Products and Market Share
Key Offerings
- SON-1010: An IL-12 FHAB intended for systemic administration. Currently in Phase 1 clinical trials. Competitors include companies developing IL-12 therapeutics or other cancer immunotherapies. Market share information is not publicly available as it is pre-commercialization.
- SON-080: IL-6 FHAB for myelosuppression indications. Competitors are companies developing products for Chemotherapy-Induced Neutropenia (CIN) such as Amgen (Neulasta) or Coherus BioSciences (UDENYCA). Currently in pre-clinical development. Market share information is not publicly available as it is pre-clinical.
Market Dynamics
Industry Overview
The oncology therapeutics market is highly competitive and rapidly evolving, with significant investment in novel immunotherapies and targeted treatments. Key trends include personalized medicine, combination therapies, and the development of therapies that modulate the tumor microenvironment.
Positioning
Sonnet Biotherapeutics is positioned as a clinical-stage company focused on cytokine-based immunotherapies using its proprietary FHAB technology. Its competitive advantage lies in its ability to target cytokines to the tumor microenvironment, potentially improving efficacy and reducing systemic toxicity.
Total Addressable Market (TAM)
The global oncology market is projected to reach hundreds of billions of USD in the coming years. Sonnet aims to capture a portion of this market by developing effective immunotherapies.
Upturn SWOT Analysis
Strengths
- Proprietary FHAB technology
- Focus on targeted cytokine delivery
- Experienced leadership team
- Novel approach to cancer immunotherapy
Weaknesses
- Early-stage clinical development
- Limited financial resources
- High risk associated with drug development
- Reliance on successful clinical trial outcomes
Opportunities
- Potential for strategic partnerships
- Expansion into new cancer indications
- Advancements in immuno-oncology
- Growing demand for targeted therapies
Threats
- Competition from larger pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
- Technological advancements from competitors
Competitors and Market Share
Key Competitors
- NVS
- MRK
- BMY
Competitive Landscape
Sonnet competes with larger pharmaceutical companies and other biotechnology firms developing cancer immunotherapies. Its FHAB technology offers a potential competitive advantage, but it faces significant challenges in terms of resources and market access.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by research and development progress, clinical trial initiations, and strategic partnerships.
Future Projections: Future projections are dependent on successful clinical trial outcomes, regulatory approvals, and market acceptance of its products. Analyst estimates vary.
Recent Initiatives: Recent initiatives include advancing its clinical trials for SON-1010 and pre-clinical development of SON-080, seeking strategic partnerships, and securing funding.
Summary
Sonnet Biotherapeutics is an early-stage oncology company leveraging its FHAB platform. Its strength lies in innovative cytokine-based therapies and targeted drug delivery. The company needs to successfully navigate clinical trials and secure funding to realize its potential. Competition and regulatory hurdles remain critical challenges.
Similar Companies
AGEN
Agenus Inc
AGEN
Agenus Inc
XOMA
XOMA Corp
XOMA
XOMA Corp
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Third-party Financial Data Providers
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sonnet Biotherapeutics Holdings Inc
Exchange NASDAQ | Headquaters Princeton, NJ, United States | ||
IPO Launch date 2006-10-31 | Founder, Chairman, CEO & President Dr. Pankaj Mohan Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://www.sonnetbio.com |
Full time employees 13 | Website https://www.sonnetbio.com | ||
Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 to treat chemotherapy-induced peripheral neuropathy (CIPN), and diabetic peripheral neuropathy; SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer; SON-1411, a bifunctional combination of human interleukin 18 (IL-18) inhibitor binding protein and single-chain human IL-12 (IL-12) for solid tumor cancers; and SON-1400, a monofunctional fusion protein comprising the IL-18 binding protein resistant domain linked to the FHAB. It has a license agreement with New Life Therapeutics Pte, Ltd. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.